Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Alex du Rand
Observed names:
A. du Rand,
du Rand, Alex
Institution:
University of Auckland
Observed institutions:
University of Auckland,
Maurice Wilkins Centre
ORCID:
0000-0002-9481-4149
Observed ORCID:
0000-0002-9481-4149
OpenAlex ID:
A5023158932
Unintended CRISPR-Cas9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene-editing in human cells
2023
·
John Murray Topp Hunt
, Christopher Allan Samson
, et al.
·
Human Genetics
·
149
PDF
Epidermolysis Bullosa: A Review of the Tissue-Engineered Skin Substitutes Used to Treat Wounds
2022
·
Alex du Rand
, John M. T. Hunt
, et al.
·
Molecular Diagnosis & Therapy
·
22
PDF
Highly efficient CRISPR /Cas9‐mediated exon skipping for recessive dystrophic epidermolysis bullosa
2024
·
Alex du Rand
, John Hunt
, et al.
·
Bioengineering & Translational Medicine
·
12
PDF
Efficient Dual Cas9 Nickase Correction of a Prevalent Pathogenic LAMB3 Variant for Junctional Epidermolysis Bullosa
2024
·
Alex du Rand
, John Hunt
, et al.
·
JID Innovations
·
7
A bioinformatic analysis of gene editing off‐target loci altered by common polymorphisms, using ‘PopOff’
2024
·
Christopher Samson
, Alex du Rand
, et al.
·
Journal of the Royal Society of New Zealand
·
5
Developing CRISPR-Based Therapies for Epidermolysis Bullosa: A Comprehensive Review of Current Strategies
2026
·
Alex du Rand
, Ben Buttle
, et al.
·
Drugs
·
4
PDF
Enhanced HDR-mediated correction of heterozygous COL7A1 mutations for recessive dystrophic epidermolysis bullosa
2025
·
John M.T. Hunt
, Alex du Rand
, et al.
·
Molecular Therapy — Nucleic Acids
·
4
Human keratinocytes grown at a gas-permeable interface in vitro stratify correctly to generate engineered human epidermis
2024
·
Vaughan Feisst
, Lisa Y.Y. Zhou
, et al.
·
Cytotherapy
·
3
PDF
A PepFect14 analog improves non‐viral CRISPR delivery in primary human cells to facilitate genome editing and repair
2026
·
Alex du Rand
, Courtney Masterson
, et al.
·
Bioengineering & Translational Medicine
PDF
Advancing the Development of a CRISPR/Cas9-Based Gene Editing Therapy for Epidermolysis Bullosa
2025
·
du Rand, Alex
·
ResearchSpace (University of Auckland)
Therapeutic Genome Editing for Severe Monogenic Skin Disorders
2024
·
J.M. Hunt
, A. du Rand
, et al.
·
Cytotherapy
Author response for "Highly efficient CRISPR /Cas9‐mediated exon skipping for recessive dystrophic epidermolysis bullosa"
2023
·
Alex du Rand
, John Hunt
, et al.
·
Publons reviews and discussion
Show more works
View as search
Works count:
13
Citation count:
206
H-index:
5
I10-index:
3
Year
Topic
Type